We are live on ! Find out more
TCRR

TCR2 Therapeutics Inc. Common Stock
TCRR

Delisted

TCRR was delisted on the 31st of May, 2023.

Back to rankings

Fund managers haven’t disclosed any holdings of TCRR yet.

TCRR Hedge Fund Activity: Q2 2023 in Review

0 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in TCR2 Therapeutics Inc. Common Stock (TCRR) for Q2 2023, worth a combined $0 — down 100% from $31.4M a quarter earlier.

Sellers outnumbered buyers: 59 funds closed out of TCRR and 0 opened new positions — a net loss of 59 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was MPM Asset Management, exiting entirely with an estimated $6.08M sold.

  • 0 institutional investors held TCR2 Therapeutics Inc. Common Stock (TCRR) as of Q2 2023, down from 59 in Q1 2023.
  • Funds reported $0 of TCR2 Therapeutics Inc. Common Stock stock for Q2 2023, down 100% quarter-over-quarter.
  • 0 funds opened new TCR2 Therapeutics Inc. Common Stock positions in Q2 2023 and 59 closed out, a net change of -59 holders.
  • The largest TCR2 Therapeutics Inc. Common Stock seller in Q2 2023 was MPM Asset Management, an estimated $6.08M sold.

Based on aggregated 13F filings for Q2 2023.